Johnson Fistel, PLLP is investigating Beta Bionics for potential securities law violations related to possibly misleading statements about the company's growth and new patient starts. The probe follows Beta Bionics' disclosure of slower growth in new patient starts for Q4 2025, which fell short of analyst expectations and showed a significant slowdown from previous quarters. This investigation could impact investors who suffered losses based on the company's public statements. Investors affected are encouraged to contact Johnson Fistel to explore their legal options.
The final significant IPO of August was priced this week, accompanied by a direct listing and two SPAC offerings. Defense technology company Lyntris priced its downsized IPO below the expected range. The IPO market is expected to remain quiet next we...
Canada halted trade negotiations with the US, citing unfair last-minute changes to the proposed terms. This decision came as the US prepared to impose 50% tariffs on $28 billion of Canadian goods. Canada responded by matching these tariffs and plans ...
European stocks, represented by the STOXX 600 index, have experienced a seven-day losing streak following a modest seven-day winning streak. This recent decline aligns with similar downward trends in US equities, indicating a broader market pullback....
Intel recently sold $20 billion worth of its stock at $95 per share. Since the sale, the stock price has dropped and is now trading below $93. This decline means investors who bought at the offering price are facing immediate losses. The price moveme...
Masayoshi Son holds 67% of SoftBank's U.S. stock portfolio in Intel shares. Despite this large stake, SoftBank did not purchase any additional Intel shares in the last quarter. This suggests a pause or cautious approach in expanding their investment ...
